PIVKA-II is a candidate marker for monitoring the effects of the oral anticoagulant warfarin

Loebstein, 2001, Interindividual variability in sensitivity to warfarin—Nature or nurture?, Clin Pharmacol Ther, 70, 159, 10.1067/mcp.2001.117444 Kimmel, 2008, Warfarin therapy: in need of improvement after all these years, Expert Opin Pharmacother, 9, 677, 10.1517/14656566.9.5.677 Chan, 1987, Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation, Br J Clin Pharmacol, 24, 621, 10.1111/j.1365-2125.1987.tb03221.x Hirsh, 1992, Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range, Chest, 102, 312S Costa, 2000, Therapeutic monitoring of warfarin: the appropriate response marker, J Pharm Pharmacol, 52, 1405, 10.1211/0022357001777405 Presnell, 2002, The vitamin K-dependent carboxylase, Thromb Haemost, 87, 937, 10.1055/s-0037-1613115 Baek, 2009, Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP, Hepatogastroenterology, 56, 763 Umeki, 1990, Levels of acarboxy prothrombin (PIVKA-II) and coagulation factors in warfarin-treated patients, Med Lab Sci, 47, 103 Wen, 2008, Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes, Clin Pharmacol Ther, 84, 83, 10.1038/sj.clpt.6100453 Iwahashi, 2007, Clinical utility of highly sensitive measurement of the PIVKA-II in anticoagulant therapy patients treated with warfarin, Fukuoka Daigaku igaku kiyō, 34, 65